Success in rheumatoid arthritis trials is conventionally measured as achieving low disease activity or remission (DAS28 <3.2 or <2.6). Approximately 40–60% of published trial participants met these endpoints within 3–6 months of MSC infusion, though many required concurrent DMARDs. Complete drug-free remission is rare; most responders required maintenance conventional therapy. Response rates are higher in early disease (<2 years) and lower in longstanding seropositive RA. Patient selection and disease stage strongly influence outcomes, with established erosive disease responding less robustly than early inflammatory cases.
Clinical evidence in rheumatoid arthritis shows encouraging preliminary signals. Seven recruiting trials indicate sustained clinical interest and patient demand. Published trials have documented reductions in serum inflammatory markers (IL-6, TNF-α) and improvements in Disease Activity Score (DAS28) following MSC infusion, with some patients achieving low-disease-activity remission. However, many studies are small and uncontrolled, lacking the rigorous blinding and long-term follow-up expected of modern rheumatology trials. Comparisons with established DMARDs (disease-modifying antirheumatic drugs) are sparse; MSCs may complement rather than replace conventional immunosuppression. Relapse following initial improvement occurs in a proportion of participants, particularly when conventional therapy is withdrawn.
Am I a candidate? → · Rheumatoid Arthritis: full overview → · Rheumatoid Arthritis cost → · Cost →
Medically reviewed by StemCellAtlas’s editorial team with Dr Polina Krasenova (Haematologist · Clinical Haematology & Integrative Oncology · 15+ yrs cell therapy) of partner clinic Stem Plus (Sofia), against ISSCR, FDA & EMA guidance. Educational information, not medical advice; figures indicative.
位于欧盟核心的 GMP 认证再生医学诊所——费用 3,000–8,000 欧元起，仅为美国或德国价格的一小部分。为来自 50 多个国家的国际患者提供个性化方案。
免费医疗评估